EP2195036A4 - COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE - Google Patents

COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE

Info

Publication number
EP2195036A4
EP2195036A4 EP08725637A EP08725637A EP2195036A4 EP 2195036 A4 EP2195036 A4 EP 2195036A4 EP 08725637 A EP08725637 A EP 08725637A EP 08725637 A EP08725637 A EP 08725637A EP 2195036 A4 EP2195036 A4 EP 2195036A4
Authority
EP
European Patent Office
Prior art keywords
radioisotops
tumors
compositions
treatment
direct administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08725637A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2195036A1 (en
Inventor
R Keith Frank
Kenneth Mcmillan
Jaime Simon
H Max Loy
Stanley D Stearns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gabriel Institute Inc
IsoTherapeutics Group LLC
Original Assignee
IsoTherapeutics Group LLC
Gabriel Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IsoTherapeutics Group LLC, Gabriel Institute Inc filed Critical IsoTherapeutics Group LLC
Publication of EP2195036A1 publication Critical patent/EP2195036A1/en
Publication of EP2195036A4 publication Critical patent/EP2195036A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP08725637A 2007-10-05 2008-02-15 COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE Withdrawn EP2195036A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99785607P 2007-10-05 2007-10-05
US99787307P 2007-10-05 2007-10-05
PCT/US2008/002026 WO2009045230A1 (en) 2007-10-05 2008-02-15 Compositions for treatment of tumors by direct administration of a radioisotope

Publications (2)

Publication Number Publication Date
EP2195036A1 EP2195036A1 (en) 2010-06-16
EP2195036A4 true EP2195036A4 (en) 2011-03-09

Family

ID=40526495

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08725637A Withdrawn EP2195036A4 (en) 2007-10-05 2008-02-15 COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE

Country Status (4)

Country Link
EP (1) EP2195036A4 (enExample)
JP (1) JP2010540627A (enExample)
CA (1) CA2701537A1 (enExample)
WO (1) WO2009045230A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008232A2 (en) 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
DOP2010000279A (es) * 2009-09-18 2012-06-15 Sari Asher Llc Composiciones radiofarmaceuticas no-coloidales sin sellar y metodos para el tratamiento de tejido anormal
WO2011152909A2 (en) * 2010-03-09 2011-12-08 Kurion, Inc. Isotope-specific separation and vitrification using ion-specific media
GB2490317A (en) 2011-04-19 2012-10-31 Dspi Ltd Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy
KR102006599B1 (ko) * 2011-12-21 2019-08-01 아이소테라퓨틱스 그룹 엘엘씨 방사성 조성물 및 그의 치료적 사용 방법
WO2013191781A2 (en) 2012-03-26 2013-12-27 Kurion, Inc. Selective regeneration of isotope-specific media resins in systems for separation of radioactive isotopes from liquid waste materials

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313273A1 (en) * 1987-10-14 1989-04-26 Australian Nuclear Science And Technology Organisation Macroaggregates for radiation synovectomy
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610751A4 (en) * 2001-04-26 2006-05-24 Univ Texas THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
AU2005290229A1 (en) * 2004-09-24 2006-04-06 Biosphere Medical, Inc. Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
EP0313273A1 (en) * 1987-10-14 1989-04-26 Australian Nuclear Science And Technology Organisation Macroaggregates for radiation synovectomy
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONG D L ET AL: "Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide", EUROPEAN JOURNAL OF NUCLEAR MEDICINE 2002 DE LNKD- DOI:10.1007/S00259-001-0696-Y, vol. 29, no. 2, 2002, pages 221 - 230, XP002618948, ISSN: 0340-6997 *
MCCREADY V R ET AL: "The potential of intratumoural unsealed radioactive source therapy.", EUROPEAN JOURNAL OF NUCLEAR MEDICINE MAY 2001 LNKD- PUBMED:11383859, vol. 28, no. 5, May 2001 (2001-05-01), pages 567 - 569, XP002618949, ISSN: 0340-6997 *
See also references of WO2009045230A1 *

Also Published As

Publication number Publication date
EP2195036A1 (en) 2010-06-16
WO2009045230A1 (en) 2009-04-09
JP2010540627A (ja) 2010-12-24
CA2701537A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
LT2478907T (lt) Kompozicijos vėžiui gydyti
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
EA201070786A1 (ru) Бензофуропиримидиноны
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EP1765391A4 (en) BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
DE202012013074U8 (de) Zusammensetzungen zur Behandlung von HCV
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
EP2249752C0 (en) OBESITY TREATMENT DEVICE
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
EA201170832A1 (ru) Пуриновые соединения
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
EP2579936A4 (en) INTRAGASTRIC DEVICE FOR TREATING OBESITY
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
EP2249765A4 (en) DAPSONE TO TREAT THE ROSACEA
EP2195036A4 (en) COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GABRIEL INSTITUTE, INC.

Owner name: ISOTHERAPEAUTICS GROUP LLC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110209

17Q First examination report despatched

Effective date: 20120514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150901